Foresite Capital Management I, LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Reported portfolio value by quarter (20 quarters reported)

$552M $9.38M

Q4 13 Q4 14 Q4 19 Q4 20 Q4 21 Q3 22

$103M in Q4 2013 → $21.4M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.

Holding	% of portfolio	Activity	Shares	Value
10x Genomics, Inc.	100.0%	Unchanged	750,000	$21.4M

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

quarter ended September 30, 2022 · filed November 14, 2022

No position changes this quarter.

quarter ended June 30, 2022 · filed August 12, 2022

Company	Action	Shares changed	Value of change	% of portfolio
E Epizyme, Inc.	Exited	−143,759	−$165K	—

quarter ended March 31, 2022 · filed May 13, 2022

No position changes this quarter.

quarter ended December 31, 2021 · filed February 11, 2022

Company	Action	Shares changed	Value of change	% of portfolio
Novavax, Inc.	Exited	−66,810	−$13.9M	—
AP Acceleron Pharma Inc.	Exited	−19,100	−$3.29M	—
E Epizyme, Inc.	Trimmed	−150,000	−$375K	0.3%

quarter ended September 30, 2021 · filed November 12, 2021

No position changes this quarter.

quarter ended June 30, 2021 · filed August 16, 2021

Company	Action	Shares changed	Value of change	% of portfolio
10x Genomics, Inc.	Trimmed	−250,000	−$49M	88.5%

quarter ended March 31, 2021 · filed May 17, 2021

Company	Action	Shares changed	Value of change	% of portfolio
10x Genomics, Inc.	Trimmed	−250,000	−$45.3M	91.3%

quarter ended December 31, 2020 · filed February 16, 2021

Company	Action	Shares changed	Value of change	% of portfolio
10x Genomics, Inc.	Trimmed	−1,500,000	−$212M	93.1%
E Epizyme, Inc.	Added	+50,000	+$543K	1.7%

Comments